Biogen raises guidance as topline outperforms amid ongoing cost management

Oct. 25, 2022 7:46 AM ETBiogen Inc. (BIIB)RHHBY, ESALY, ESALFBy: Dulan Lokuwithana, SA News Editor

From 2nd second to third 3rd quarter symbol. Turned wooden cubes and changed words 2nd quarter to 3rd quarter. Beautiful wooden table white background. Business happy 3rd quarter concept. Copy space.

Dzmitry Dzemidovich/iStock via Getty Images

Even as its topline continued to contract, Q3 2022 results of Alzheimer’s drug developer Biogen (NASDAQ:BIIB) exceeded the consensus on Tuesday. The company raised the 2022 guidance due mainly to better-than-expected topline

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.